S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

NovoCure Stock Forecast, Price & News

-0.54 (-0.31 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $171.84
50-Day Range
MA: $166.03
52-Week Range
Now: $171.84
Volume361,110 shs
Average Volume702,744 shs
Market Capitalization$17.49 billion
P/E Ratio904.47
Dividend YieldN/A
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and NovoTTF-100L, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products that are in Phase 2 pilot and Phase 3 pivotal trials for brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
NovoCure logo


Overall MarketRank

1.46 out of 5 stars

Medical Sector

466th out of 1,926 stocks

Surgical & Medical Instruments Industry

45th out of 169 stocks

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:NVCR



Sales & Book Value

Annual Sales$351.32 million
Book Value$2.20 per share


Net Income$-7,230,000.00


Market Cap$17.49 billion
Next Earnings Date2/25/2021 (Confirmed)
-0.54 (-0.31 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

NovoCure (NASDAQ:NVCR) Frequently Asked Questions

How has NovoCure's stock been impacted by COVID-19?

NovoCure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NVCR stock has increased by 155.0% and is now trading at $171.84.
View which stocks have been most impacted by COVID-19

Is NovoCure a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NovoCure stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View analyst ratings for NovoCure
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than NovoCure?

Wall Street analysts have given NovoCure a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NovoCure wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as NovoCure's CEO?

1,448 employees have rated NovoCure CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among NovoCure's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for NovoCure

How can I listen to NovoCure's earnings call?

NovoCure will be holding an earnings conference call on Thursday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its earnings results on Thursday, October, 29th. The medical equipment provider reported $0.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.05. The medical equipment provider had revenue of $132.70 million for the quarter, compared to analyst estimates of $120.02 million. NovoCure had a return on equity of 7.40% and a net margin of 4.26%. NovoCure's revenue for the quarter was up 44.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.02 earnings per share.
View NovoCure's earnings history

What guidance has NovoCure issued on next quarter's earnings?

NovoCure updated its FY 2020 Pre-Market earnings guidance on Monday, January, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $494.4-494.4 million, compared to the consensus revenue estimate of $482.29 million.

What price target have analysts set for NVCR?

9 Wall Street analysts have issued 12-month target prices for NovoCure's shares. Their forecasts range from $58.00 to $159.00. On average, they expect NovoCure's share price to reach $112.38 in the next twelve months. This suggests that the stock has a possible downside of 34.6%.
View analysts' price targets for NovoCure
or view Wall Street analyst' top-rated stocks.

Are investors shorting NovoCure?

NovoCure saw a increase in short interest in December. As of December 31st, there was short interest totaling 5,880,000 shares, an increase of 17.8% from the December 15th total of 4,990,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is currently 5.0 days. Currently, 6.8% of the company's shares are sold short.
View NovoCure's Short Interest

Who are some of NovoCure's key competitors?

What other stocks do shareholders of NovoCure own?

Who are NovoCure's key executives?

NovoCure's management team includes the following people:
  • Mr. William F. Doyle, Exec. Chairman (Age 58, Pay $1.66M)
  • Mr. Asaf Danziger, Pres, CEO & Director (Age 54, Pay $1.69M)
  • Mr. Wilhelmus C. M. Groenhuysen, Chief Operating Officer (Age 62, Pay $1.02M)
  • Mr. Pritesh Shah, Chief Commercial Officer (Age 42, Pay $725.6k)
  • Prof. Yoram Palti, Founder & CTO (Age 82)
  • Ms. Ashley Cordova, CFO & VP of Investor Relations
  • Mr. Todd C. Longsworth, Gen. Counsel (Age 45)
  • Dr. Ely Benaim, Chief Medical Officer (Age 59)
  • Mr. Uri Weinberg M.D., Ph.D., Chief Science Officer
  • Mr. Frank Leonard, Chief Devel. Officer

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by a variety of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.12%), Scout Investments Inc. (0.10%), Peregrine Capital Management LLC (0.07%), Northstar Asset Management LLC (0.02%), TIAA FSB (0.01%) and Total Clarity Wealth Management Inc. (0.01%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Charles G Phillips III, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure

Which major investors are selling NovoCure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Peregrine Capital Management LLC, Exchange Traded Concepts LLC, Sowell Financial Services LLC, Scout Investments Inc., Northstar Asset Management LLC, and Total Clarity Wealth Management Inc.. Company insiders that have sold NovoCure company stock in the last year include Asaf Danziger, Ashley Cordova, Ely Benaim, Gabriel Leung, Jeryl L Hilleman, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for NovoCure
or view top insider-selling stocks.

Which major investors are buying NovoCure stock?

NVCR stock was purchased by a variety of institutional investors in the last quarter, including TIAA FSB, Brookstone Capital Management, Kestra Advisory Services LLC, Sheets Smith Wealth Management, Kovack Advisors Inc., Redpoint Investment Management Pty Ltd, XR Securities LLC, and Diversified Trust Co.
View insider buying and selling activity for NovoCure
or or view top insider-buying stocks.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $171.84.

How big of a company is NovoCure?

NovoCure has a market capitalization of $17.49 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis. NovoCure employs 782 workers across the globe.

What is NovoCure's official website?

The official website for NovoCure is www.novocure.com.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.